Autres langues Seres Therapeutics, Inc.

Actions

MCRB

US81750R2013

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:43:38 23/09/2026			Varia. 5j.	Varia. 1 janv.
3,805 ^USD	-5,35%		-9,74%	-74,46%

13/08	Seres Therapeutics dépose un projet d'offre universelle de 300 millions de dollars	MT
05/08	Seres Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

21/09	Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from S&P Global BMI Index
09/09	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/09	Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
13/08	Seres Therapeutics Files $300 Million Mixed Shelf
05/08	Seres Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Seres Therapeutics: Q2 Earnings Snapshot
05/08	Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
08/07	Seres Therapeutics Announces Early Clinical Data Showing Potential For SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
08/07	Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell
08/07	Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
25/06	Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
08/06	Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
05/06	Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
01/06	Seres Therapeutics, Inc. Announces Resignation of Hans-Juergen Woerle as Director, Effective May 31, 2026
12/05	Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
05/05	Seres Therapeutics: Q1 Earnings Snapshot
05/05	Seres Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
05/05	Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
04/05	Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
04/05	Seres Therapeutics Presents Preclinical Data At Digestive Disease Week 2026 Supporting Ser-603, A Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
21/04	CATL launches battery innovations to strengthen global market leadership
20/04	Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
20/04	Seres Therapeutics Showcases Ser-155 Data And Live Biotherapeutic Insights At Escmid Global
15/04	China's CATL beats first quarter forecasts, boosting market dominance
09/04	Seres Therapeutics to Present at CARB-X Investor Day